Search
SQ-109
go.drugbank.com/drugs/DB05186InvestigationalCurrently in Phase I clinical trials, SQ-109 could replace one or more drugs in the current first-line TB drug regimen, simplify therapy, and shorten the TB treatment regimen.
Phenylalanine
go.drugbank.com/drugs/DB00120ApprovedInvestigationalNutraceuticalPhenylalanine is an essential aromatic amino acid that is a precursor of melanin, dopamine, noradrenalin (norepinephrine), and thyroxine.
Mixtures: Nutriflex Lipid special ohne Elektrolyte Emulsion zur Infusion, Nutriflex Omega special ohne Elektrolyte B. Braun Emulsion zur InfusionTryptophan
go.drugbank.com/drugs/DB00150ApprovedInvestigationalNutraceuticalWithdrawnAn essential amino acid that is necessary for normal growth in infants and for nitrogen balance in adults. It is a precursor of indole alkaloids in plants. It is a precursor of serotonin (hence its use as an antidepressant and sleep aid)...
Mixtures: Nutriflex Lipid special ohne Elektrolyte Emulsion zur Infusion, Nutriflex Omega special ohne Elektrolyte B. Braun Emulsion zur InfusionThreonine
go.drugbank.com/drugs/DB00156ApprovedInvestigationalNutraceuticalAn essential amino acid occurring naturally in the L-form, which is the active form. It is found in eggs, milk, gelatin, and other proteins.
Mixtures: Nutriflex Lipid special ohne Elektrolyte Emulsion zur Infusion, Nutriflex Omega special ohne Elektrolyte B. Braun Emulsion zur InfusionVenetoclax
go.drugbank.com/drugs/DB11581ApprovedInvestigationalA new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one
Thyrotropin alfa
go.drugbank.com/drugs/DB00024ApprovedInvestigationalVet approvedheterodimeric glycoprotein comprised of two non-covalently linked subunits, an alpha subunit of 92 amino acid residues containing two N-linked glycosylation sites and a beta subunit of 112 residues containing one
Repotrectinib
go.drugbank.com/drugs/DB16826ApprovedInvestigational[A262056] ROS1 mutations are one of the defined oncogenic drives of NSCLC, and the solvent-front mutation ROS1 G2032R is responsible for 50 to 60% of [crizotinib]-resistant cases.
Synonyms: (3R,6S,)-45-FLUORO-3,6-DIMETHYL-5-OXA-2,8-DIAZA-1(5,3)-PYRAZOLO(1,5-A)PYRIMIDINA-4(1,2)-BENZENANONAPHAN-9-ONE, (7S,13R)-11-Fluoro-7,13-Dimethyl-6,7,13,14-Tetrahydro-1,15-Ethenopyrazolo[4,3-F][1,4,8,10]Benzoxatriazacyclotridecin-4(5H)-OneFondaparinux
go.drugbank.com/drugs/DB00569ApprovedInvestigationalFondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan su...
Tofisopam
go.drugbank.com/drugs/DB08811InvestigationalTofisopam (marketed under brand names Emandaxin and Grandaxin) is a 2,3-benzodiazepine drug which is a benzodiazepine derivative. In contrast to classical 1,4-benzodiazepines, the compound does not bind to the benzodiazepine binding site...
Atoltivimab
go.drugbank.com/drugs/DB15898ApprovedInvestigational[A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection.